{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T18:13:44Z","timestamp":1789496024708,"version":"build-2803163510"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,9,14]],"date-time":"2022-09-14T00:00:00Z","timestamp":1663113600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,9,14]],"date-time":"2022-09-14T00:00:00Z","timestamp":1663113600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100002332","name":"Semmelweis University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100002332","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Endocr Disord"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>IDegLira is a fixed-ratio combination of insulin degludec and liraglutide with proven efficacy against simpler regimens and non-inferiority against basal-bolus insulin therapy. However, the evaluation of its real-world effectiveness is hindered by technical issues and requires further exploration. Thus we aimed to compare effectiveness of insulin degludec\/liraglutide (IDegLira) versus intensified conventional insulin therapy (ICT) for type 2 diabetes in a real-world setting.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>This retrospective cohort study from an outpatient clinic in Hungary included people who initiated IDegLira due to inadequate glycaemic control (HbA1c &gt;\u20097.0% [53.0\u2009mmol\/mol]) with oral and\/or injectable antidiabetic drugs. Data were compared with a historical cohort who initiated ICT. Outcomes included HbA1c, body weight, and hypoglycaemia differences over 18\u2009months of follow-up.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Data were included from 227 and 72 people who initiated IDegLira and ICT, respectively. Estimated mean difference (MD) in HbA1c at 18\u2009months favoured IDegLira versus ICT (MD 0.60, 95% CI 0.88\u20130.32 [MD 6.6\u2009mmol\/mol, 95% CI 9.6\u20133.5]). More people reached target HbA1c \u22647.0% (53.0\u2009mmol\/mol) with IDegLira than ICT (odds ratio 3.36, 95% CI 1.52\u20137.42). IDegLira treatment was associated with weight loss compared with gain for ICT (MD 6.7\u2009kg, 95% CI 5.0\u20138.5). The hazard ratio for hypoglycaemia comparing IDegLira with ICT was 0.18 (95% CI 0.08\u20130.49).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Treatment with IDegLira over 18\u2009months resulted in greater HbA1c reductions, weight loss versus gain, and a lower rate of hypoglycaemia versus ICT in people with type 2 diabetes.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12902-022-01139-8","type":"journal-article","created":{"date-parts":[[2022,9,14]],"date-time":"2022-09-14T16:03:00Z","timestamp":1663171380000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Real-world effectiveness of IDegLira compared with intensified conventional insulin therapy in adults with type 2 diabetes: a retrospective cohort study"],"prefix":"10.1186","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0197-7687","authenticated-orcid":false,"given":"S\u00e1ndor","family":"Sz\u00e9pk\u00fati","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8808-5595","authenticated-orcid":false,"given":"Szilvia","family":"Bandur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0713-6894","authenticated-orcid":false,"given":"G\u00e1bor","family":"Kov\u00e1cs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6791-3080","authenticated-orcid":false,"given":"Tam\u00e1s","family":"Ferenci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6624-9621","authenticated-orcid":false,"given":"M\u00e1rk M.","family":"Sv\u00e9bis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piroska","family":"Turbucz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6234-3936","authenticated-orcid":false,"given":"\u00c1d\u00e1m G.","family":"Tab\u00e1k","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,9,14]]},"reference":[{"issue":"Suppl 2","key":"1139_CR1","doi-asserted-by":"publisher","first-page":"S151","DOI":"10.2337\/dc09-S301","volume":"32","author":"VA Fonseca","year":"2009","unstructured":"Fonseca VA. Defining and characterizing the progression of type 2 diabetes. Diabetes Care. 2009;32(Suppl 2):S151\u20136.","journal-title":"Diabetes Care"},{"issue":"9833","key":"1139_CR2","doi-asserted-by":"publisher","first-page":"2279","DOI":"10.1016\/S0140-6736(12)60283-9","volume":"379","author":"AG Tabak","year":"2012","unstructured":"Tabak AG, Herder C, Rathmann W, Brunner EJ, Kivimaki M. Prediabetes: a high-risk state for diabetes development. Lancet. 2012;379(9833):2279\u201390.","journal-title":"Lancet."},{"issue":"21","key":"1139_CR3","doi-asserted-by":"publisher","first-page":"2005","DOI":"10.1001\/jama.281.21.2005","volume":"281","author":"RC Turner","year":"1999","unstructured":"Turner RC, Cull CA, Frighi V, Holman RR. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK prospective diabetes study (UKPDS) group. JAMA. 1999;281(21):2005\u201312.","journal-title":"JAMA."},{"issue":"12","key":"1139_CR4","doi-asserted-by":"publisher","first-page":"2669","DOI":"10.2337\/dci18-0033","volume":"41","author":"MJ Davies","year":"2018","unstructured":"Davies MJ, D'Alessio DA, Fradkin J, Kernan WN, Mathieu C, Mingrone G, et al. Management of Hyperglycemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of diabetes (EASD). Diabetes Care. 2018;41(12):2669\u2013701.","journal-title":"Diabetes Care"},{"issue":"Suppl 1","key":"1139_CR5","doi-asserted-by":"publisher","first-page":"S111","DOI":"10.2337\/dc21-S009","volume":"44","author":"DA American","year":"2021","unstructured":"American DA. 9. Pharmacologic approaches to glycemic treatment: standards of medical Care in Diabetes-2021. Diabetes Care. 2021;44(Suppl 1):S111\u2013S24.","journal-title":"Diabetes Care"},{"issue":"9626","key":"1139_CR6","doi-asserted-by":"publisher","first-page":"1753","DOI":"10.1016\/S0140-6736(08)60762-X","volume":"371","author":"J Weng","year":"2008","unstructured":"Weng J, Li Y, Xu W, Shi L, Zhang Q, Zhu D, et al. Effect of intensive insulin therapy on beta-cell function and glycaemic control in patients with newly diagnosed type 2 diabetes: a multicentre randomised parallel-group trial. Lancet. 2008;371(9626):1753\u201360.","journal-title":"Lancet."},{"key":"1139_CR7","doi-asserted-by":"publisher","first-page":"204201881984469","DOI":"10.1177\/2042018819844694","volume":"10","author":"S Khunti","year":"2019","unstructured":"Khunti S, Khunti K, Seidu S. Therapeutic inertia in type 2 diabetes: prevalence, causes, consequences and methods to overcome inertia. Ther Adv Endocrinol Metab. 2019;10:2042018819844694.","journal-title":"Ther Adv Endocrinol Metab"},{"issue":"9548","key":"1139_CR8","doi-asserted-by":"publisher","first-page":"1696","DOI":"10.1016\/S0140-6736(06)69705-5","volume":"368","author":"DJ Drucker","year":"2006","unstructured":"Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet. 2006;368(9548):1696\u2013705.","journal-title":"Lancet."},{"issue":"3","key":"1139_CR9","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1177\/2042018817752315","volume":"9","author":"W Nuffer","year":"2018","unstructured":"Nuffer W, Guesnier A, Trujillo JM. A review of the new GLP-1 receptor agonist\/basal insulin fixed-ratio combination products. Ther Adv Endocrinol Metab. 2018;9(3):69\u201379.","journal-title":"Ther Adv Endocrinol Metab"},{"issue":"3","key":"1139_CR10","doi-asserted-by":"publisher","first-page":"152","DOI":"10.2337\/diaspect.29.3.152","volume":"29","author":"SL Anderson","year":"2016","unstructured":"Anderson SL, Trujillo JM. Basal insulin use with GLP-1 receptor agonists. Diabetes Spectr. 2016;29(3):152\u201360.","journal-title":"Diabetes Spectr"},{"issue":"10","key":"1139_CR11","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1111\/dom.12498","volume":"17","author":"SC Gough","year":"2015","unstructured":"Gough SC, Bode BW, Woo VC, Rodbard HW, Linjawi S, Zacho M, et al. One-year efficacy and safety of a fixed combination of insulin degludec and liraglutide in patients with type 2 diabetes: results of a 26-week extension to a 26-week main trial. Diabetes Obes Metab. 2015;17(10):965\u201373.","journal-title":"Diabetes Obes Metab"},{"issue":"11","key":"1139_CR12","doi-asserted-by":"publisher","first-page":"2926","DOI":"10.2337\/dc14-0785","volume":"37","author":"JB Buse","year":"2014","unstructured":"Buse JB, Vilsboll T, Thurman J, Blevins TC, Langbakke IH, Bottcher SG, et al. Contribution of liraglutide in the fixed-ratio combination of insulin degludec and liraglutide (IDegLira). Diabetes Care. 2014;37(11):2926\u201333.","journal-title":"Diabetes Care"},{"issue":"1","key":"1139_CR13","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1007\/s13300-016-0218-3","volume":"8","author":"S Linjawi","year":"2017","unstructured":"Linjawi S, Bode BW, Chaykin LB, Courreges JP, Handelsman Y, Lehmann LM, et al. The efficacy of IDegLira (insulin Degludec\/Liraglutide combination) in adults with type 2 diabetes inadequately controlled with a GLP-1 receptor agonist and Oral therapy: DUAL III randomized clinical trial. Diabetes Ther. 2017;8(1):101\u201314.","journal-title":"Diabetes Ther"},{"issue":"2","key":"1139_CR14","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1111\/dme.13256","volume":"34","author":"HW Rodbard","year":"2017","unstructured":"Rodbard HW, Bode BW, Harris SB, Rose L, Lehmann L, Jarlov H, et al. Safety and efficacy of insulin degludec\/liraglutide (IDegLira) added to sulphonylurea alone or to sulphonylurea and metformin in insulin-naive people with type 2 diabetes: the DUAL IV trial. Diabet Med. 2017;34(2):189\u201396.","journal-title":"Diabet Med"},{"issue":"9","key":"1139_CR15","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1001\/jama.2016.1252","volume":"315","author":"I Lingvay","year":"2016","unstructured":"Lingvay I, Perez Manghi F, Garcia-Hernandez P, Norwood P, Lehmann L, Tarp-Johansen MJ, et al. Effect of insulin glargine up-titration vs insulin Degludec\/Liraglutide on glycated hemoglobin levels in patients with uncontrolled type 2 diabetes: the DUAL V randomized clinical trial. JAMA. 2016;315(9):898\u2013907.","journal-title":"JAMA."},{"issue":"6","key":"1139_CR16","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1111\/dom.12892","volume":"19","author":"SB Harris","year":"2017","unstructured":"Harris SB, Kocsis G, Prager R, Ridge T, Chandarana K, Halladin N, et al. Safety and efficacy of IDegLira titrated once weekly versus twice weekly in patients with type 2 diabetes uncontrolled on oral antidiabetic drugs: DUAL VI randomized clinical trial. Diabetes Obes Metab. 2017;19(6):858\u201365.","journal-title":"Diabetes Obes Metab"},{"issue":"5","key":"1139_CR17","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.2337\/dc17-1114","volume":"41","author":"LK Billings","year":"2018","unstructured":"Billings LK, Doshi A, Gouet D, Oviedo A, Rodbard HW, Tentolouris N, et al. Efficacy and safety of IDegLira versus basal-bolus insulin therapy in patients with type 2 diabetes uncontrolled on metformin and basal insulin: the DUAL VII randomized clinical trial. Diabetes Care. 2018;41(5):1009\u201316.","journal-title":"Diabetes Care"},{"issue":"8","key":"1139_CR18","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1016\/S2213-8587(19)30184-6","volume":"7","author":"VR Aroda","year":"2019","unstructured":"Aroda VR, Gonzalez-Galvez G, Gron R, Halladin N, Haluzik M, Jermendy G, et al. Durability of insulin degludec plus liraglutide versus insulin glargine U100 as initial injectable therapy in type 2 diabetes (DUAL VIII): a multicentre, open-label, phase 3b, randomised controlled trial. Lancet Diabetes Endocrinol. 2019;7(8):596\u2013605.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"11","key":"1139_CR19","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1016\/S2213-8587(14)70174-3","volume":"2","author":"SC Gough","year":"2014","unstructured":"Gough SC, Bode B, Woo V, Rodbard HW, Linjawi S, Poulsen P, et al. Efficacy and safety of a fixed-ratio combination of insulin degludec and liraglutide (IDegLira) compared with its components given alone: results of a phase 3, open-label, randomised, 26-week, treat-to-target trial in insulin-naive patients with type 2 diabetes. Lancet Diabetes Endocrinol. 2014;2(11):885\u201393.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"1139_CR20","unstructured":"Novo Nordisk A\/S. Xultophy Summary of Product Characteristics 2020 [Available from: https:\/\/www.medicines.org.uk\/emc\/product\/3469."},{"key":"1139_CR21","doi-asserted-by":"publisher","first-page":"3","DOI":"10.24121\/dh.2017.1","volume":"25","author":"J Ge","year":"2017","unstructured":"Ge J. Clinical practice guideline \u2013 diagnosis, antihyperglycaemic treatment and care of patients with diabetes in adulthood. Diabetologia Hungarica. 2017;25:3\u201377.","journal-title":"Diabetologia Hungarica"},{"key":"1139_CR22","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-319-19425-7","volume-title":"Regression modeling strategies: with applications to linear models, logistic and ordinal regression, and survival analysis","author":"F Harrell","year":"2015","unstructured":"Harrell F. Regression modeling strategies: with applications to linear models, logistic and ordinal regression, and survival analysis. Berlin: Springer; 2015."},{"key":"1139_CR23","unstructured":"R Core Team. R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna 2019 [Available from: http:\/\/www.R-project.org\/."},{"issue":"12","key":"1139_CR24","doi-asserted-by":"publisher","first-page":"3231","DOI":"10.1007\/s13300-021-01156-1","volume":"12","author":"RJ McCrimmon","year":"2021","unstructured":"McCrimmon RJ, Lamotte M, Ramos M, Alsaleh AJO, Souhami E, Lew E. Cost-effectiveness of iGlarLixi versus iDegLira in type 2 diabetes mellitus inadequately controlled by GLP-1 receptor agonists and Oral Antihyperglycemic therapy. Diabetes Ther. 2021;12(12):3231\u201341.","journal-title":"Diabetes Ther"},{"issue":"4","key":"1139_CR25","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1080\/13696998.2017.1409228","volume":"21","author":"M Evans","year":"2018","unstructured":"Evans M, Billings LK, Hakan-Bloch J, Slothuus U, Abrahamsen TJ, Andersen A, et al. An indirect treatment comparison of the efficacy of insulin degludec\/liraglutide (IDegLira) and insulin glargine\/lixisenatide (iGlarLixi) in patients with type 2 diabetes uncontrolled on basal insulin. J Med Econ. 2018;21(4):340\u20137.","journal-title":"J Med Econ"},{"issue":"17","key":"1139_CR26","doi-asserted-by":"publisher","first-page":"1789","DOI":"10.1080\/14656566.2017.1400011","volume":"18","author":"X Cai","year":"2017","unstructured":"Cai X, Gao X, Yang W, Ji L. Comparison between insulin degludec\/liraglutide treatment and insulin glargine\/lixisenatide treatment in type 2 diabetes: a systematic review and meta-analysis. Expert Opin Pharmacother. 2017;18(17):1789\u201398.","journal-title":"Expert Opin Pharmacother"},{"issue":"9","key":"1139_CR27","doi-asserted-by":"publisher","first-page":"2309","DOI":"10.1111\/dom.13343","volume":"20","author":"MI Maiorino","year":"2018","unstructured":"Maiorino MI, Chiodini P, Bellastella G, Scappaticcio L, Longo M, Esposito K, et al. Free and fixed-ratio combinations of basal insulin and GLP-1 receptor agonists versus basal insulin intensification in type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials. Diabetes Obes Metab. 2018;20(9):2309\u201313.","journal-title":"Diabetes Obes Metab"},{"issue":"11","key":"1139_CR28","doi-asserted-by":"publisher","first-page":"2542","DOI":"10.1111\/dom.13840","volume":"21","author":"ML Morieri","year":"2019","unstructured":"Morieri ML, Rigato M, Frison V, Simioni N, D'Ambrosio M, Tadiotto F, et al. Fixed versus flexible combination of GLP-1 receptor agonists with basal insulin in type 2 diabetes: a retrospective multicentre comparative effectiveness study. Diabetes Obes Metab. 2019;21(11):2542\u201352.","journal-title":"Diabetes Obes Metab"},{"issue":"2","key":"1139_CR29","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1007\/s13300-017-0234-y","volume":"8","author":"D Sofra","year":"2017","unstructured":"Sofra D. Glycemic control in a real-life setting in patients with type 2 diabetes treated with IDegLira at a single Swiss center. Diabetes Ther. 2017;8(2):377\u201384.","journal-title":"Diabetes Ther"},{"issue":"4","key":"1139_CR30","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1111\/dom.13182","volume":"20","author":"H Price","year":"2018","unstructured":"Price H, Bluher M, Prager R, Phan TM, Thorsted BL, Schultes B, et al. Use and effectiveness of a fixed-ratio combination of insulin degludec\/liraglutide (IDegLira) in a real-world population with type 2 diabetes: results from a European, multicentre, retrospective chart review study. Diabetes Obes Metab. 2018;20(4):954\u201362.","journal-title":"Diabetes Obes Metab"},{"issue":"5","key":"1139_CR31","doi-asserted-by":"publisher","first-page":"1869","DOI":"10.1007\/s13300-019-0673-8","volume":"10","author":"Z Taybani","year":"2019","unstructured":"Taybani Z, Botyik B, Katko M, Gyimesi A, Varkonyi T. Simplifying complex insulin regimens while preserving good glycemic control in type 2 diabetes. Diabetes Ther. 2019;10(5):1869\u201378.","journal-title":"Diabetes Ther"},{"issue":"1","key":"1139_CR32","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1007\/s13300-019-00725-9","volume":"11","author":"C Melzer-Cohen","year":"2020","unstructured":"Melzer-Cohen C, Chodick G, Naftelberg S, Shehadeh N, Karasik A. Metabolic control and adherence to therapy in type 2 diabetes mellitus patients using IDegLira in a real-world setting. Diabetes Ther. 2020;11(1):185\u201396.","journal-title":"Diabetes Ther"},{"key":"1139_CR33","first-page":"CD013228","volume":"12","author":"B Fullerton","year":"2018","unstructured":"Fullerton B, Siebenhofer A, Jeitler K, Horvath K, Semlitsch T, Berghold A, et al. Short-acting insulin analogues versus regular human insulin for adult, non-pregnant persons with type 2 diabetes mellitus. Cochrane Database Syst Rev. 2018;12:CD013228.","journal-title":"Cochrane Database Syst Rev"},{"issue":"2","key":"1139_CR34","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1016\/j.diabres.2008.04.007","volume":"81","author":"M Monami","year":"2008","unstructured":"Monami M, Marchionni N, Mannucci E. Long-acting insulin analogues versus NPH human insulin in type 2 diabetes: a meta-analysis. Diabetes Res Clin Pract. 2008;81(2):184\u20139.","journal-title":"Diabetes Res Clin Pract"},{"key":"1139_CR35","doi-asserted-by":"publisher","first-page":"4221","DOI":"10.2147\/DMSO.S216054","volume":"13","author":"ML Morieri","year":"2020","unstructured":"Morieri ML, Avogaro A, Fadini GP. Long-acting injectable GLP-1 receptor agonists for the treatment of adults with type 2 diabetes: perspectives from clinical practice. Diabetes Metab Syndr Obes. 2020;13:4221\u201334.","journal-title":"Diabetes Metab Syndr Obes"}],"container-title":["BMC Endocrine Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12902-022-01139-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12902-022-01139-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12902-022-01139-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,14]],"date-time":"2022-09-14T16:03:06Z","timestamp":1663171386000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcendocrdisord.biomedcentral.com\/articles\/10.1186\/s12902-022-01139-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,14]]},"references-count":35,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["1139"],"URL":"https:\/\/doi.org\/10.1186\/s12902-022-01139-8","relation":{},"ISSN":["1472-6823"],"issn-type":[{"value":"1472-6823","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,14]]},"assertion":[{"value":"30 May 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 August 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 September 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All study related procedures have been performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments. Local ethical approval was obtained from the Ethics Committee of Pest County Fl\u00f3r Ferenc Hospital, Kistarcsa, Hungary; Registration number: 119\/17\/2017. The need for informed consent was waived in accordance with Hungarian laws by the Ethics Committee of Pest County Fl\u00f3r Ferenc Hospital, Kistarcsa, Hungary.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"SSz has received consultancy and advisory board fees from Lilly Hung\u00e1ria, Novo Nordisk, and Sanofi; and speaker fees from Lilly Hung\u00e1ria, Novo Nordisk, and Sanofi. SzB has received consultancy and advisory board fees from Sanofi; and speaker fees from MSD, Novo Nordisk, and Sanofi. GK has received speaker fees from IPSEN, and Sanofi. TF has no potential sources of conflict of interest to disclose. MMS has received speaker fees from Eli Lilly, Novo Nordisk, Boehringer Ingelheim, Medtronic, 77 Elektronika, Krka and Egis Pharmaceuticals. PT has received consultancy, advisory board and speaker fees from Novo Nordisk and Sanofi. AGT has received consultancy and advisory board fees from 77 Elektronika, Lilly Hung\u00e1ria, and Sanofi; and speaker fees from AstraZeneca, Berlin-Chemie, Eli Lilly, Novo Nordisk, and Sanofi. AGT was supported by the Ministry of Innovation and Technology of Hungary from the National Research, Development and Innovation Fund (2021 Thematic Excellence Programme funding scheme, TKP2021-NKTA-47).","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"229"}}